Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061 Younossi, 2015, Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085 Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001 Tsochatzis, 2011, Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy, J Hepatol, 54, 650, 10.1016/j.jhep.2010.07.033 Sasso, 2016, Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the fibroscan: a pilot study assessing diagnostic accuracy, Ultrasound Med Biol, 42, 92, 10.1016/j.ultrasmedbio.2015.08.008 Sasso, 2010, Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 de Ledinghen, 2014, Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations, J Hepatol, 60, 1026, 10.1016/j.jhep.2013.12.018 Jun, 2017, A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis, PLoS One, 12, e0182784, 10.1371/journal.pone.0182784 Runge, 2018, MR Spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis, Radiology, 286, 547, 10.1148/radiol.2017162931 Myers, 2012, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624 Tapper, 2016, The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 111, 677, 10.1038/ajg.2016.49 Naveau, 2017, Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 29, 1022, 10.1097/MEG.0000000000000919 Chan, 2017, Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population, United European Gastroenterol J, 5, 76, 10.1177/2050640616646528 Park, 2017, Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease, Gastroenterology, 152, 598, 10.1053/j.gastro.2016.10.026 Garg, 2018, Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients, Surg Obes Relat Dis, 14, 81, 10.1016/j.soard.2017.09.005 de Ledinghen, 2017, Controlled attenuation parameter (CAP) with the XL probe of the fibroscan((R)): a comparative study with the m probe and liver biopsy, Dig Dis Sci, 62, 2569, 10.1007/s10620-017-4638-3 Vuppalanchi, 2018, Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease, Hepatology, 67, 134, 10.1002/hep.29489 Siddiqui, 2019, Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 156, 10.1016/j.cgh.2018.04.043 Bossuyt, 2015, STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies, BMJ, 351, h5527, 10.1136/bmj.h5527 Petta, 2015, The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease, Hepatology, 62, 1101, 10.1002/hep.27844 Petta, 2017, Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values, Hepatology, 65, 1145, 10.1002/hep.28843 Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038/ajg.2012.331 de Ledinghen, 2012, Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R), J Hepatol, 56, 833, 10.1016/j.jhep.2011.10.017 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 de Ledinghen, 2008, Transient elastography (FibroScan), Gastroenterol Clin Biol, 32, 58, 10.1016/S0399-8320(08)73994-0 de Ledinghen, 2012, Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography, Liver Int, 32, 911, 10.1111/j.1478-3231.2012.02820.x Myers, 2012, Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography, Liver Int, 32, 902, 10.1111/j.1478-3231.2012.02781.x 2016 Caussy, 2018, Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis, Hepatology, 67, 1348, 10.1002/hep.29639 Wong, 2017, Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter, J Hepatol, 67, 577, 10.1016/j.jhep.2017.05.005 Lee, 2010, Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease, Dig Liver Dis, 42, 503, 10.1016/j.dld.2009.08.002 Boursier, 2013, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, 57, 1182, 10.1002/hep.25993 de Franchis, 2015, Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension, J Hepatol, 63, 743, 10.1016/j.jhep.2015.05.022 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Roulot, 2011, Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years, Gut, 60, 977, 10.1136/gut.2010.221382 Harris, 2017, Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review, Lancet Gastroenterol Hepatol, 2, 288, 10.1016/S2468-1253(16)30205-9 Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 Newsome, 2018, Guidelines on the management of abnormal liver blood tests, Gut, 67, 6, 10.1136/gutjnl-2017-314924